Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mutation screening for tyrosinaemia type I.

S K Heath1, R G F Gray, P McKiernan

  • 1Clinical Chemistry Department, Birmingham Children's Hospital, Birmingham, UK. stephanie.heath@bhamchildrens.wmids.nhs.uk

Journal of Inherited Metabolic Disease
|January 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neonatal screening: current trends and quality control in the United Kingdom.

Rinsho byori. The Japanese journal of clinical pathology·1998
Same author

Current concepts of shoulder arthroplasty.

Instructional course lectures·1998
Same author

Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort.

Scandinavian journal of rheumatology·1998
Same author

Inhibition of protein synthesis by nitric oxide correlates with cytostatic activity: nitric oxide induces phosphorylation of initiation factor eIF-2 alpha.

Molecular medicine (Cambridge, Mass.)·1998
Same author

Comparative pupil dilation using phenylephrine alone or in combination with tropicamide.

Ophthalmology·1998
Same author

The intuition of the negative in Playing and reality.

The International journal of psycho-analysis·1998
Same journal

Biallelic Loss-Of-Function Variant in ATP5ME Is Associated With Severe and Early Onset Oxidative Phosphorylation Deficiency.

Journal of inherited metabolic disease·2026
Same journal

Beyond Upper Airway Involvement: Evidence of Intrinsic Lung Disease in a Mouse Model of Mucopolysaccharidosis I.

Journal of inherited metabolic disease·2026
Same journal

Immune Dysregulation in Branched Chain Organic Acidemias.

Journal of inherited metabolic disease·2026
Same journal

Long Term Follow-Up After Transplantation in Propionic Acidemia: A Retrospective French Pediatric and Adult Cohort Study.

Journal of inherited metabolic disease·2026
Same journal

Tri-Parametric Assessment of α-Galactosidase A Activity, lysoGb3 and X-Inactivation Aids Genotype-Phenotype Categorization of Fabry Disease Female Patients.

Journal of inherited metabolic disease·2026
Same journal

Mapping the Severity of Phenylalanine Hydroxylase Deficiency.

Journal of inherited metabolic disease·2026
See all related articles

Researchers developed a new mutation screening strategy for tyrosinaemia type I. This approach identified six previously unknown mutations in the fumarylacetoacetate hydrolase (FAH) gene.

Area of Science:

  • Biochemistry
  • Genetics
  • Molecular Biology

Background:

  • Tyrosinaemia type I is a rare genetic disorder.
  • It is caused by mutations in the fumarylacetoacetate hydrolase (FAH) gene.
  • Accurate mutation identification is crucial for diagnosis and genetic counseling.

Purpose of the Study:

  • To develop an efficient mutation screening strategy for tyrosinaemia type I.
  • To identify novel mutations in the FAH gene associated with the disorder.

Main Methods:

  • Development of a comprehensive mutation screening strategy.
  • Application of the strategy to patients with tyrosinaemia type I.
  • DNA sequencing and analysis of the FAH gene.

Main Results:

Related Experiment Videos

  • Successful development of a novel mutation screening strategy.
  • Identification of six new mutations in the FAH gene.
  • These mutations expand the known spectrum of genetic alterations in tyrosinaemia type I.

Conclusions:

  • The developed strategy is effective for mutation detection in tyrosinaemia type I.
  • The identified novel mutations contribute to understanding the genetic basis of the disease.
  • This work aids in improving diagnostic capabilities and genetic counseling for affected families.